Savara (SVRA) Amortization of Deferred Charges (2015 - 2026)
Savara's (SVRA) quarterly Amortization of Deferred Charges came in at $42000.0 in Q1 2026, down 40.0% year-on-year from $70000.0 in Q1 2025, and down 87.46% on a QoQ basis from $335000.0 in Q4 2025.
Savara (SVRA) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends
Savara (SVRA) has 12 years of Amortization of Deferred Charges data on file, last reported at $42000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges fell 40.0% year-over-year to $42000.0 in Q1 2026; TTM through Mar 2026 was $425000.0, a 55.68% increase from a year earlier, with the FY2025 full-year figure at $453000.0, up 67.16% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $42000.0, down from $335000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for SVRA reached as high as $335000.0 in Q4 2025 and fell as low as -$87000.0 in Q2 2022.
- Historically, Amortization of Deferred Charges has averaged $69000.0 across 5 years, with a median of $68000.0 in 2023.
- Across the five-year window, Amortization of Deferred Charges slumped 163.5% in 2022 and surged 4200.0% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $35000.0 in 2022, then surged by 94.29% to $68000.0 in 2023, then changed by 0.0% to $68000.0 in 2024, then jumped by 392.65% to $335000.0 in 2025, then sank by 87.46% to $42000.0 in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $42000.0 in Q1 2026, $335000.0 in Q4 2025, and -$81000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,000.00 |
| Mar 31, 2026 | 42,000.00 |
| Dec 31, 2025 | 335,000.00 |
| Dec 31, 2025 | 335,000.00 |
| Sep 30, 2025 | -81,000.00 |
| Sep 30, 2025 | -81,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Mar 31, 2025 | 70,000.00 |
| Mar 31, 2025 | 70,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 68,000.00 |
| Mar 31, 2024 | 68,000.00 |
| Dec 31, 2023 | 68,000.00 |
| Dec 31, 2023 | 68,000.00 |